Quarter 4, 2011
Microwave ablation used in hi-tech liver resection The Accu2i pMTA applicator has become the first microwave ablation device documented to have played a crucial role in a liver resection using the da Vinci Surgical System. The operation on a lesion measuring 3.5cm was carried out by Dr Adrian Legaspi, MD, at Mount Sinai Medical Center, Florida, in October. Dr Legaspi used the da Vinci’s state-of-the-art robotic technology to operate through tiny incisions in the patient’s abdomen. Using intra-operative ultrasound and direct visual guidance he located the target coagulation zones and used the de Vinci system to place the Accu2i pMTA around the diseased tissue for six 120 watt, two minute burns. Dr Legaspi then proceeded to cut out the lesion while carrying out three further two minute burns at 180 watts. At the end of the operation the removed tissue measured approximately 5.5cm, providing an excellent margin, and the collection canister was empty, with only trace amounts of blood
in the suction tubing. In total, the patient was in theatre for two and half hours. Stuart McIntyre, Chief Executive of Microsulis Medical Ltd, said: “We are delighted that the versatility of the Accu2i pMTA applicator has been highlighted as part of this technologically advanced, minimally invasive procedure.” The Accu2i pMTA applicator – part of the Acculis Microwave Tissue Ablation (MTA) system - is the most powerful soft tissue ablation product available, combining extreme ease of use with the widest range of clinical applications. It is a single high power, high frequency 2.45GHz, saline-cooled needle that is between three to 10 times faster than other devices. It can coagulate tissue masses of up to 5.6cm in size in just six minutes.
The da Vinci Surgical System ©2011 Intuitive Surgical, Inc
Mount Sinai Medical Center is the largest private independent teaching hospital in South Florida and has used Microsulis Medical’s Acculis MTA system since April 2011. Dr Legaspi is working on a full write up of this liver resection case for publication in the near future.
Effective microwave ablation techniques highlighted at APHPBA The effectiveness of microwave ablation in surgery was highlighted at the recent Asian Pacific Hepato-Pancreato-Biliary Association (APHPBA) Congress in Melbourne, Australia. Leading clinicians presented their findings at a symposium hosted by Microsulis Medical at the premier event for clinicians in the southern hemisphere. The symposium – ‘Microwave: effective ablation, supporting surgery’ – was moderated by senior
liver surgery professors from the University of Edinburgh, Royal Infirmary Edinburgh, in the UK and Hopital Beaujon in Paris, France. More than 100 delegates were in attendance. Presentations during the session focused on both the technical
and histopathological aspects of microwave ablation. In particular, clinicians from the USA, Europe and Asia shared their clinical experiences and data from using Microsulis Medical’s Accu2i pMTA applicator – part of the Acculis Microwave Tissue Ablation (MTA) system.
Responsibly sourced packaging Microsulis Medical has teamed up with the UK’s largest specialist employer of people with disabilities and health conditions to produce new packaging for the Accu2i pMTA applicator. Last year, Remploy found jobs in mainstream employment for more than 20,000 people with a range of disabilities and other disadvantages. That is in addition to offering training for over 75,000 clients and operating a national network of 54 factories, employing more than 2,300 disabled people. Remploy’s packaging team, based in Norwich, has manufactured a sleek black box inline with Microsulis Medical’s microwave tissue ablation branding. Customers will start seeing the new packaging in circulation from December 2011. For more information about Remploy, go to: www.remploy.co.uk.
Safety first The Acculis Microwave Tissue Ablation (MTA) system has achieved ETL accreditation, certifying its compliance with international safety standards. Achieving this recognition is an important step towards global commercialisation of Microsulis Medical’s minimally invasive medical devices. The Acculis MTA system has already been used in more than 100 medical centres world-wide and its roll out will be stepped up in 2012. The ETL mark will now appear on Microsulis Medical’s Sulis VpMTA Generator, which powers the Acculis range of microwave tissue ablation devices. Stuart McIntyre, Microsulis Medical’s Chief Executive, said: “We are pleased to be able to assure new and existing customers that our products meet the highest safety standards. The ETL mark is a trusted accreditation, which will prove extremely valuable as we continue to commercialise our innovative technology in emerging markets.”
Supporting good causes During past six months, Microsulis Medical staff have taken part in several events raising hundreds of pounds for charity. Fundraising activities have included participating in a quiz night in aid of Cancer Research UK, entering a team in the ARK Medical Trust’s annual golf day and supporting a local family through the Lennox Children’s Cancer Fund.
Broadening the reach of microwave ablation New distribution partners have been appointed in Taiwan and Turkey to support the global commercialisation of the Acculis Microwave Tissue Ablation (MTA) system. Medical device promoters China Spring and Gelisim Medikal are in the process of registering Microsulis’ products in Taiwan and Turkey respectively. Partner negotiations are ongoing in Austria, Germany, Japan and Spain. Meanwhile, hospital trials have been happening in Sweden and France, where the Acculis MTA system has an expanding customer base. Details about how to contact our distribution partners are available at www.microsulis.com. Alternatively, contact our sales team whose details are listed on the back of this newsletter.
Harnessing the benefits of microwave ablation Interventional radiologists are well versed in weighing up the benefits of minimally invasive procedures against the well documented side affects and lengthy treatment times associated with established ablation techniques. But, thanks to advances in ablative therapies they can now explore other options. Microwave is the newest ablative tool available to clinicians, bringing with it the ability to offer a different option to patients who do not qualify for more traditional procedures. It can also reduce treatment costs for hospitals.
Here are just some of the reasons why clinicians have added the Acculis Microwave Tissue Ablation (MTA) system to their treatment tool box. The benefits for surgeons and radiologists: • The short time required to create large coagulations means that many more sites can be coagulated within a given operative window • Speed and predictability means that the desired coagulation zone can be reliably and decisively achieved
• The development of the zone is predominantly spherical from the outset meaning that progressive scalable coagulations can be created using power, time parameters and real time imaging • The extreme simplicity of operation of the system ensures that coagulations can be performed during open, laparoscopic and percutaneous procedures without placing complex additional equipment management demands on the operative team • The ability to monitor the development of the coagulation zone in real time using ultrasound or CT imaging means operators can accurately monitor coagulation progress and confidently achieve the desired coagulation margins • These features mean that oncologists, surgeons and radiologists can consider a wider range of treatment possibilities when designing treatment strategies for patients. The benefits for hospitals and medical centres: • The speed of treatment using the Acculis MTA system translates directly into reduced operating costs when compared to Radio Frequency Ablation or low frequency microwave products
The Accu2i pMTA applicator, part of the Acculis MTA system
• Reduced in-patient stay costs due to rapid recovery and low complication rates • Increased facility revenue due to increased patient throughput. The benefits for patients: • The Acculis MTA system is designed to be less invasive, meaning less time in theatre and less time to recover from the operation • As with all ablation therapies, complications are possible. However data shows that these are no more likely with the Acculis MTA system than with lower frequency ablation systems or RFA. To find out more about the Acculis MTA system go to www.microsulis.com.
Green matters Microsulis Medical has been recognised for its commitment to managing its environmental impact. During its annual audit against guidelines from the International Organization for Standardization (ISO), the company was
found to be compliant with its Environmental Management System (ISO 14001:2004). This includes meeting legal requirements to run a green business, showing continual improvement in its environmental performance and preventing pollution.
During the next year, Microsulis aims to further reduce energy consumption, reuse more paper and improve its local carbon footprint. This newsletter is printed on Forest Stewardship Council (FSC) approved paper, sourced from sustainable woodland. page 3
Microwave ablation at MINA The benefits of microwave tissue ablation (MTA) were presented at the recent Medical Imaging Nurses Association (MINA) national meeting in Adelaide, Australia.
Contact us Microsulis Medical’s expert product sales team is always happy to hear from you. If you would like to find out more about the company’s products or have questions about your existing system, please get in touch. EUROPE David Murdoch +41 22 348 9111 email@example.com UK & IRELAND Carrie Breen +44 (0) 7795 027388 firstname.lastname@example.org Ian Malcolmson +44 (0) 7557 284268 email@example.com NORTH AMERICA Tim Dwyer +1 240 565 3955 firstname.lastname@example.org GLOBAL BUSINESS DEVELOPMENT Daniel Canning +44 (0) 7500 012247 email@example.com
The conference for Australian and New Zealand medical imaging nurses was attended by more than 200 delegates from across both countries. Registered Nurse Aime Smith, from the Medical Imaging Department at Flinders Medical Centre in Adelaide, spoke about the Centre’s use of Microsulis Medical’s Acculis MTA system. The hospital bought the system a year ago and has carried out more than 20 hepatocarcinoma cases using CT and three cases laparoscopically using intra-operative ultrasound. RN Smith discussed the selection criteria used by Flinders to determine patient suitability and the pre-operative work, and pre and post-op care required for patients undergoing this procedure. To date all of the cases performed at Flinders have been under general anaesthesia and with day or short stay patients.
Supporting the academic community In 2011, Microsulis Medical was the proud sponsor of health sector conferences staged on five continents. Most recently, the company was gold level sponsors of AUGIS in Belfast, Northern Ireland, platinum sponsors of APHPBA in Melbourne, Australia, major supporters of BSIR in Glasgow, UK, and silver sponsors of PSGBI in Dublin, Ireland.
If you are attending any major radiology or oncology industry events in 2012, look out for Microsulis Medical. For a full list of the conferences and symposia at which the company is registered to exhibit see the Events page on www.microsulis.com.
GENERAL ENQUIRIES +44 (0)2392 240011 firstname.lastname@example.org
Microsulis online www.microsulis.com
Meet the team
As well as visiting Microsulis Medical’s website, you can find it on Twitter, Facebook and Linked In.
Latest news and product updates from the specialists in microwave tissue ablation, Microsulis Medical Ltd. www.microsulis.com